Results 21 to 30 of about 8,937 (172)

Chemical Reactivity of Chlorambucil in Organic Solvents: Influence of 4-Chloro Butyronitrile Nucleophile to Voltammogram Profiles

International Journal of Electrochemical Science, 2011
Chlorambucil is one of anticancer drug that has been mainly used in the treatment of cancer disease. It is an alkylating agent and can be given orally.
Henry Setiyanto, Vienna Saraswaty, Rukman Hertadi, Indra Noviandri, Buchari Buchari   +4 more
doaj   +1 more source

Obinutuzumab in Combination with Alternative Chlorambucil Schedules in Front-Line Treatment of Chronic Lymphocytic Leukemia: A Study by KroHem, the Croatian Cooperative Group for Hematologic Diseases

Biomedicines
Background/Objectives: Obinutuzumab was approved for front-line treatment of chronic lymphocytic leukemia in combination with chlorambucil pulses administered every 2 wks.
Igor Aurer, Ozren Jakšić, Sandra Bašić-Kinda, Karla Mišura-Jakobac, Jasminka Sinčić-Petričević, Sabina Novaković-Coha, Davor Galušić, Hrvoje Holik, Toni Valković, Dubravka Županić-Krmek, Ida Hude-Dragičević, Vibor Milunović, Vlatko Pejša   +12 more
doaj   +1 more source

Chlorambucil-Induced Acute Interstitial Pneumonitis

Case Reports in Hematology, 2014
Chlorambucil is an alkylating agent commonly used in treatment of chronic lymphocytic leukemia (CLL). We report a case of interstitial pneumonitis developing in an 83-year-old man 1.5 months after completing a six-month course of chlorambucil for CLL ...
Hammad Shafqat, Adam J. Olszewski
doaj   +1 more source

Benzotriazine Di-Oxide Prodrugs for Exploiting Hypoxia and Low Extracellular pH in Tumors

Molecules, 2019
Extracellular acidification is an important feature of tumor microenvironments but has yet to be successfully exploited in cancer therapy. The reversal of the pH gradient across the plasma membrane in cells that regulate intracellular pH (pHi) has ...
Michael P. Hay, Hong Nam Shin, Way Wua Wong, Wan Wan Sahimi, Aaron T.D. Vaz, Pooja Yadav, Robert F. Anderson, Kevin O. Hicks, William R. Wilson   +8 more
doaj   +1 more source

Chemoimmunotherapy Administration Protocol Design for the Treatment of Leukemia through Mathematical Modeling and In Silico Experimentation

Pharmaceutics, 2022
Cancer with all its more than 200 variants continues to be a major health problem around the world with nearly 10 million deaths recorded in 2020, and leukemia accounted for more than 300,000 cases according to the Global Cancer Observatory. Although new
Paul A. Valle, Raul Garrido, Yolocuauhtli Salazar, Luis N. Coria, Corina Plata   +4 more
doaj   +1 more source

Chemotherapeutic Potential of Fluorouracil‐Platinum (IV) Prodrugs Against Cisplatin‐Resistant Colorectal Cancer Cells

Chemistry – A European Journal, EarlyView.
ABSTRACT Fluorouracil‐platinum(IV) prodrugs represent a novel class of multimechanistic chemotherapeutics with enhanced anticancer potential. The prodrugs PtIVP‐5FUMeOBut and PtIV56‐5FUMeOBut were actualized by derivatising the clinical drug 5‐fluorouracil (5FU) and coordinating it to platinum(IV) complexes, leveraging the established cytotoxicity of ...
Maria George Elias, Aleen Khoury, Shadma Fatima, Timothy J. Mann, Shawan Karan, Meena Mikhael, Paul de Souza, Christopher P. Gordon, Kieran F. Scott, Janice R. Aldrich‐Wright   +9 more
wiley   +1 more source

Successful rescue treatment using chlorambucil for presumed recurrence of sinonasal lymphoma in a cat

Journal of Feline Medicine and Surgery Open Reports, 2023
Case summary A 12-year-old male neutered domestic shorthair cat presented with a 2-week history of serous unilateral nasal discharge, swelling of the nasal bridge and sneezing.
Sho Goto, Fumikazu Muto, Ryota Iwasaki, Takashi Mori   +3 more
doaj   +1 more source

Control of Gemcitabine Activity With Blue and Red Light

Chemistry – A European Journal, EarlyView.
Treating cancer with chemotherapy is generally associated with many side effects, which can be addressed by selectively releasing the desired drugs with visible light. Sixteen new blue light‐activatable cytostatics were introduced, with the gemcitabine derivative exhibiting ideal properties.
Nils F. Kersten, Konstantin L. Stock, Marius Hyprath, Hannah Weisser, Timo Weinrich, Dieter Steinhilber, Alexander Heckel   +6 more
wiley   +1 more source

Thrombocytosis and tumour distribution predict outcome in dogs with hepatocellular carcinoma: A multi‐institutional retrospective analysis

Veterinary Record, EarlyView.
Abstract Background Hepatocellular carcinoma (HCC) is the most common canine hepatobiliary tumour. This study aimed to determine which criteria influenced outcome of HCC in a modern population of dogs across eight institutions. Methods The medical records of 106 dogs with HCC were retrospectively reviewed.
Emily A. Janik, MacKenzie A. Pellin, Dawn M. Clarke   +2 more
wiley   +1 more source

First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial

Haematologica, 2022
iLLUMINATE is a randomized, open-label phase III study of ibrutinib plus obinutuzumab (n=113) versus chlorambucil plus obinutuzumab (n=116) as first-line therapy for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Carol Moreno, Richard Greil, Fatih Demirkan, Alessandra Tedeschi, Bertrand Anz, Loree Larratt, Martin Simkovic, Jan Novak, Vladimir Strugov, Devinder Gill, John G. Gribben, Kevin Kwei, Sandra Dai, Emily Hsu, James P. Dean, Ian W. Flinn   +15 more
doaj   +1 more source